Lupin is currently trading at Rs. 979.75, up by 9.65 points or 0.99% from its previous closing of Rs. 970.10 on the BSE.
The scrip opened at Rs. 1021.00 and has touched a high and low of Rs. 1021.00 and Rs. 979.25 respectively. So far 74751 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1034.55 on 17-Aug-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1021.00 and Rs. 960.50 respectively. The current market cap of the company is Rs. 44557.33 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.88% and 12.91% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir HFA. The company’s generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India.
ProAir HFA (Albuterol Sulfate Inhalation Aerosol) is the registered trademark of Teva Branded Pharmaceutical Products R&D, Inc. (Teva) and is indicated for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms. The total Albuterol Sulfate Inhalation Aerosol market had U.S. sales of approximately $2.9 billion, of which the ProAir HFA market accounted for $1.3 billion (IQVIA MAT June 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.